| Clinical data | |
|---|---|
| Other names | ALEPH-6; DOT-6; 4-Phenylthio-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-phenylthioamphetamine; 4-PhS-DMA |
| Routes of administration | Oral |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | "Probably long" (at least 12 hours) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H21NO2S |
| Molar mass | 303.42 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Aleph-6, or ALEPH-6, also known as 4-phenylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is one of the Aleph series of compounds.
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph-6's dose as greater than 40 mg orally and its duration as "probably long". The effects of Aleph-6 have been reported to include "un-worldliness", among others. It was reported to have synergized with LSD when taken in combination with it. Overall however, Shulgin regarded Aleph-6 as a "disappointment" and that it may be a "forever threshold thing".
The chemical synthesis of Aleph-6 has been described. The 2C analogue, 2C-T-6, has never been synthesized.
Aleph-6 was first described in the literature by Shulgin in PiHKAL in 1991. It is a controlled substance in Canada under phenethylamine blanket-ban language.
| Phenethylamines |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphetamines |
| ||||||||||||||||
| Phentermines |
| ||||||||||||||||
| Cathinones |
| ||||||||||||||||
| Phenylisobutylamines (and further-extended) |
| ||||||||||||||||
| Catecholamines (and close relatives) |
| ||||||||||||||||
| Cyclized phenethylamines |
| ||||||||||||||||
| Related compounds |
| ||||||||||||||||